Treatment with anti-CGRP monoclonal antibodies in patients with idiopathic intracranial hypertension: a pilot study

被引：0
|
作者：
Krajnc, N. [1 ]
Macher, S. [1 ]
Marik, W. [2 ]
Michl, M. [3 ]
Novak, K. [4 ]
Woeber, C. [1 ]
Pemp, B. [3 ]
Bsteh, G. [1 ]
机构：
[1] Med Univ Vienna, Dept Neurol, Vienna, Austria
[2] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[3] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria
[4] Med Univ Vienna, Dept Neurosurg, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-253
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [31] Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
    Charleston, Larry
    Talon, Brian
    Sullivan, Christine
    Anderson, Carlton
    Kymes, Steven
    Regnier, Stephane A. A.
    Soni-Brahmbhatt, Seema
    Nahas, Stephanie J. J.
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [32] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 179 - 179
  • [33] Anti-CGRP monoclonal antibodies normalize peripheral sensitization in migraineurs
    Bartole, L.
    Granato, A.
    Deodato, M.
    D'Acunto, L.
    Garascia, G.
    Biaduzzini, F.
    Manganotti, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 374 - 374
  • [34] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
    Amy R. Tso
    Peter J. Goadsby
    Current Treatment Options in Neurology, 2017, 19
  • [35] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
    Tso, Amy R.
    Goadsby, Peter J.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2017, 19 (08)
  • [36] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 120 - 121
  • [37] Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents
    Szperka, Christina L.
    VanderPluym, Juliana
    Orr, Serena L.
    Oakley, Christopher B.
    Qubty, William
    Patniyot, Irene
    Lagman-Bartolome, Ana Marissa
    Morris, Cynthia
    Gautreaux, Jessica
    Victorio, M. Cristina
    Hagler, Suzanne
    Narula, Sona
    Candee, Meghan S.
    Cleves-Bayon, Catalina
    Rao, Rashmi
    Fryer, Robert H.
    Bicknese, Alma R.
    Yonker, Marcy
    Hershey, Andrew D.
    Powers, Scott W.
    Goadsby, Peter J.
    Gelfand, Amy A.
    HEADACHE, 2018, 58 (10): : 1658 - 1669
  • [38] Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
    Iannone, Luigi Francesco
    De Cesaris, Francesco
    Ferrari, Anita
    Benemei, Silvia
    Fattori, Davide
    Chiarugi, Alberto
    CEPHALALGIA, 2022, 42 (13) : 1323 - 1330
  • [39] Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis
    Vikelis, Michail
    Rikos, Dimitrios
    Argyriou, Andreas A.
    Dermitzakis, Emmanouil V.
    Andreou, Anna P.
    Russo, Antonio
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2025,
  • [40] DO MULTIPLE TREATMENT CYCLES WITH ANTI-CGRP MONOCLONAL ANTIBODIES MODIFY MIGRAINE COURSE?
    Aurilia, C.
    Egeo, G.
    Proietti, S.
    Torelli, P.
    Cevoli, S.
    D'Onofrio, F.
    Bonassi, S.
    Barbanti, P.
    HEADACHE, 2023, 63 : 126 - 126
12345